S'abonner

National and regional prevalence of SARS-CoV-2 antibodies in primary and secondary school children in England: the School Infection Survey, a national open cohort study, November 2021SARS-CoV-2 antibody prevalence in school children - 01/04/23

Doi : 10.1016/j.jinf.2023.02.016 
Annabel A. Powell c, Georgina Ireland c, Rebecca Leeson d, Andrea Lacey d, Ben Ford d, John Poh c, Samreen Ijaz c, Justin Shute c, Peter Cherepanov e, Richard Tedder f, Christian Bottomley g, Fiona Dawe d, Punam Mangtani g, Peter Jones d, Patrick Nguipdop-Djomo g, 1, Shamez N. Ladhani c, h, 1,

on behalf of the COVID-19 Schools Infection Survey Group

Shazaad Ahmad a, Frances Baawuah a, Joanne Beckmann a, Andrew Brent a, Bernadette Brent a, Joanna Garstang a, Ifeanyichukwu O. Okike a, Kevin Brown a, Mary Ramsay a, Chris Bonell b, Sarah Cook b, Charlotte Warren-Gash b, Jody Phelan b, James Hargreaves b, Sinead Langan b, Neisha Sundaram b, Elliot McClenaghan b, Gillian McKay b, John Edmunds b, Paul Fine b
a UKHSA, UK 
b LSHTM, UK 

c Public Health Programmes, UK Health Security Agency, London, UK 
d Office for National Statistics, Newport, UK 
e Department of Infectious Disease, Imperial College London, London, UK 
f Chromatin Structure and Mobile DNA Laboratory, The Francis Crick institute, London, UK 
g Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK 
h Paediatric Infectious Diseases Research Group, St George’s University of London, London, UK 

Corresponding author at: Public Health Programmes, UK Health Security Agency, London, UK.Public Health Programmes, UK Health Security AgencyLondonUK

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Summary

Background

SARS-CoV-2 infection rates are likely to be underestimated in children because of asymptomatic or mild infections. We aim to estimate national and regional prevalence of SARS-CoV-2 antibodies in primary (4–11 years old) and secondary (11–18 years old) school children between 10 November and 10 December 2021.

Methods

Cross-sectional surveillance in England using two-stage sampling, firstly stratifying into regions and selecting local authorities, then selecting schools according to a stratified sample within selected local authorities. Participants were sampled using a novel oral fluid-validated assay for SARS-CoV-2 spike and nucleocapsid IgG antibodies.

Results

4980 students from 117 state-funded schools (2706 from 83 primary schools, 2274 from 34 secondary schools) provided a valid sample. After weighting for age, sex, and ethnicity, and adjusting for assay accuracy, the national prevalence of SARS-CoV-2 antibodies in primary school students, who were all unvaccinated, was 40.1% (95% CI 37.3–43.0). Antibody prevalence increased with age (p < 0.001) and was higher in urban than rural schools (p = 0.01). In secondary school students, the adjusted, weighted national prevalence of SARS-CoV-2 antibodies was 82.4% (95% CI 79.5–85.1); including 71.5% (95% CI 65.7–76.8) in unvaccinated and 97.5% (95% CI 96.1–98.5) in vaccinated students. Antibody prevalence increased with age (p < 0.001), and was not significantly different in urban versus rural students (p = 0.1).

Conclusions

In November 2021, using a validated oral fluid assay, national SARS-CoV-2 seroprevalence was estimated to be 40.1% in primary school students and 82.4% in secondary school students. In unvaccinated children, this was approximately threefold higher than confirmed infections highlighting the importance of seroprevalence studies to estimate prior exposure.

Data availability

Deidentified study data are available for access by accredited researchers in the ONS Secure Research Service (SRS) for accredited research purposes under part 5, chapter 5 of the Digital Economy Act 2017. For further information about accreditation, contact Research.support@ons.gov.uk or visit the SRS website.

Le texte complet de cet article est disponible en PDF.

Keywords : Seroprevalence, SARS-CoV-2, Antibodies, Oral fluid, School pupils, COVID-19 vaccination


Plan


Crown Copyright © 2023  Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 86 - N° 4

P. 361-368 - avril 2023 Retour au numéro
Article précédent Article précédent
  • Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study
  • Andrew Evans, Cathy Qi, Jubril Omololu Adebayo, Jonathan Underwood, James Coulson, Rowena Bailey, Ronan Lyons, Adrian Edwards, Alison Cooper, Gareth John, Ashley Akbari
| Article suivant Article suivant
  • Tick-borne encephalitis: Acute clinical manifestations and severity in 581 cases from Germany, 2018–2020
  • Teresa M. Nygren, Antonia Pilic, Merle M. Böhmer, Christiane Wagner-Wiening, Simone-Beatrice Went, Ole Wichmann, Wiebke Hellenbrand

Bienvenue sur EM-consulte, la référence des professionnels de santé.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.